Articles On Recce Pharmaceuticals (ASX:RCE)

Recce Pharmaceuticals (RCE) RCE 327 Gel shows promise in treating multiple antibiotic-resistant infections under the TGA SAS Category A The gel achieved a >99.99 per cent reduction against MRSA in an ex-vivo burn wound study Clinic...

Recce Pharmaceuticals (RCE) is granted a new patent in Australia protecting its in-house R327 and R529 anti-infectives Recce is primarily focused on R327 which is the subject of an ongoing trial showing superior results so far compared...

The ASX200 closed 0.7 per cent down to finish the week. Only energy, IT and utilities sectors ended the week afloat, and then only just. Uncertainties around interest rates took a toll, exacerbated by fading hopes around China injecti...

The ASX 200 has been trading down almost a per cent  – energy’s the only sector making gains and only just. Materials has been the worst performer shedding more than 1.8 per cent. Ahead of the RBA’s interest decision next week, the Bu...

Recce Pharmaceuticals’ (RCE) phase I/II trial partner has wrapped up the second-stage dosages of its ongoing trial A third cohort of patients is now being recruited ahead of schedule The company’s flagship anti-infective UTI product...

Recce Pharmaceutical’s (RCE) flagship anti-infective UTI treatment R327 was proven to be safe last week The company’s phase I/II trial is now accelerating ahead of schedule with the help of NSW-based partner Scientia Recce expects d...

The ASX is trading well today up nearly half a per cent with only the materials and communications sectors taking a dip. ASX200 giant Woodside Energy (WDS) is up 1.5 per cent after releasing its June quarterly report. Its full-year produ...

Recce Pharmaceuticals (RCE) announces “positive” results from its completed phase one study of anti-infective R327 The trial doses R327 from 50mg to 6000mg and marks the first-in-human study to display safe and well-tolerated treatment w...

The Reserve Bank Governor Phillip Lowe would like to continue in the role he’s held since 2016. Speaking at the Australian Conference of Economists in Brisbane today, he recognised that Treasurer Jim Chalmers will reveal his decision on...

Recce Pharmaceuticals (RCE) receives $801,604 from Radium Capital as part of Recce’s future research and development tax incentive The company is now over $3 million in rebates for its R&D activities through FY23 RCE CEO James Gr...

Recce Pharmaceuticals (ASX:RCE) has announced that its Phase 1/2 clinical trial evaluating R327 at faster infusion rates has successfully dosed its first cohort of male and female subjects.

The ASX 200 has dipped just a little in early trade. Exploration company Dreadnought Resources (DRE) is up more than five per cent after defining fresh rare earths’ zones at its Mangaroon project in Western Australia. A 24-hole, 4000-...

Recce Pharmaceuticals is developing an IV-administered treatment for Urinary Tract Infections (UTIs) Its RECCE 327 formula has been observed to rapidly kill E. coli bacteria in both male and female patients The company recently woun...

Recce Pharmaceuticals (RCE) gains approval from the Human Research Ethics Committee to expand its phase I/II trial of R327 to treat UTIs The trial is assessing faster administration rates with Scientia Clinical Research facilitating the...

The ASX is tracking up in midday trade, with mining giants and the big four banks all in positive territory. In the materials space, Leo Lithium (LLL) has jumped 17.6 per cent after China’s largest lithium producer, Ganfeng, committed to...

Recce Pharmaceuticals (RCE) appoints outpatient nurses from leading healthcare provider Ascott The nurses, trained in R327 DFI treatment, will broaden the company’s diabetic foot infection (DFI) trial patient population RCE’s phase on...

The ASX opened on a higher note today, with real estate, energy, and banking stocks contributing to the overall gain. The materials sector also led the pack, climbing nearly two per cent before lunchtime. Red 5 (RED) was amongst the comp...

Recce Pharmaceuticals (RCE) secures sponsorship from the West Australian government to attend BIO Korea 2023 RCE has been selected as one of three WA companies to attend the bio-health industry conference in Seoul this week The govern...

Developing a drug that is safe and effective for public use is no easy feat. It requires years of clinical trials, extensive research, and a significant financial investment before it can be sold on the shelves of your local pharmacy. Ma...

Recce Pharmaceuticals (RCE) receives Human Research Ethics Committee (HREC) approval to start a phase I/II intravenous clinical trial of its lead R327 drug As part of the trial, RCE will assess intravenous doses of R327 at infusion rates...

Recce Pharmaceuticals (RCE) last year confirmed the safety of its R327 antibiotics treatment for human use, and now it’s working to confirm the treatment’s efficacy in the patient population. R327 is the world’s first breakthrough antibi...

Recce Pharmaceuticals (RCE) receives boost from the Australian Patent Office after announcing its ‘intent to grant’ the first of Recce’s new Patent Family 4 for anti-infectives The patent covers the “Process for Preparation of Biological...

The ASX is tipped to open slightly higher on Tuesday following the slight rise to ASX futures when they traded during New York hours on Good Friday. That said, it is shaping up to be a big week for Wall Street, with key price data and qu...

Recce Pharmaceuticals (ASX:RCE) has announced that the Australian Patent Office has issued notification of intent to grant the first of its new 'Patent Family 4' for its anti-infectives 'Process for Preparation of Biologically Activ...

The ASX 200 will open slightly higher on Tuesday Tesla to expand in China to produce mega batteries Aussie Brian Hood sues ChatGPT for defamation   The ASX is set for a modest opening on Tuesday after a mixed session in New York. At 8am A...

Energy stocks have surged in early trade after OPEC’s controversial move to cut oil production by one million barrels per day. But it’s been a boost to companies in the sector, which has risen around 1.5 per cent. TMK Energy shares al...

Recce Pharmaceuticals (RCE) pockets a further $973,144 from Radium Capital as part of Recce’s future research and development tax incentive The payment from Radium represents an accountant-verified proportion of Recce’s December to Febru...

Recce Pharmaceuticals (ASX:RCE) has received further non-dilutive funds from Radium Capital of almost $1 million as an advance payment of its R&D Tax Incentive rebate from the Australian government.

Recce Pharmaceuticals (RCE) selects CMAX Clinical Research in South Australia as the independent facility for a clinical trial to treat urinary tract infections (UTIs) The phase one and two intravenous clinical trial will assess RCE’s le...

HeraMED’s first commercial rollout in the US is progressing well Recce Pharma is set to commence Phase I/II clinical trial   Maternity care medtech company, HeraMED (ASX:HMD), says the first phase of its commercial rollout in the US is pr...

Recce Pharmaceuticals (RCE) receives ‘RECCE’ trademark from the Trade Marks Registry Intellectual Property Department in Hong Kong It bolsters the company’s IP portfolio, with issued patents and patent applications already in the biggest...

Recce Pharmaceuticals (RCE) pockets a research and development (R&D) refund of $6.21 million The cash receipt comprises $4.3 million from the Australian Tax Office for the year ending June 30, 2022, and an advance payment of $1.9 mil...

Recce receives a grant intent from the Australian Patent Office for an antivirus agent targeting mega bugs coronavirus, SARS, and HIV, growing in big pharmaceutical markets across the world. The post Recce Pharmaceuticals to Receive Austral...

The share market pared four days of gains following a mixed night on Wall Street as investors took some money off the table ahead of risk events later this week. The S&P/ASX 200 slid 20 points or 0.28 per cent to its first loss since...

Shares in Perth-founded Recce Pharmaceuticals have lifted after the company announced it had received a grant intent from the Australian Patent Office for an anti-virus agent.

The share market retreated for the first time in five sessions after Wall Street’s winning start to 2023 lost momentum. The S&P/ASX 200 declined 14 points or 0.19 per cent by mid-session. A loss today would be only the second in six...

Recce Pharmaceuticals (RCE) receives a notification of intent to grant an Australian patent for synthetic anti-infectives The grant from the Australian Patent Office relates to the RECCE 327 (R327) and RECCE 529 (R529) formulations, mar...

Recce Pharmaceuticals (RCE) receives a notification of intent to grant an Australian patent for synthetic anti-infectives The grant from the Australian Patent Office relates to the RECCE 327 (R327) and RECCE 529 (R529) formulations, mar...

MGC Pharma completes pre-clinical study on CimetrA Recce Pharma close to getting Aussie patent AdAlta gets second patent in Japan   MGC Pharma on track for FDA submission MGC Pharma (ASX:MXC) has completed the full pre-clinical rodents st...

It can take a long time to bring a new drug to market, but companies that succeed reap mighty rewards. Any time a company is working in drug manufacturing and clinical research, the compound needs to be tested on human subjects to ensure...

The long and short of 2022 is that it was a frustrating period for the Australian biotech sector but one with its fair share of rewards as the sector’s exponents furthered worthy drugs, diagnostics, devices and doodahs. For the sixth year,...

What a day it’s been, what a magic day… and other children’s song lyrics that probably won’t make much sense to anyone who has never been subjected to the unrelenting horrors of Jimmy Giggle and his clearly drug-addled owl. Anyhow – since i...

Recce Pharmaceuticals (RCE) establishes a new anti-infective research unit within the Murdoch Children’s Research Institute’s facilities in MelbourneThe company has secured a dedicated Murdoch Children’s research team of infectious disease...

Recce Pharmaceuticals (RCE) receives Human Research Ethics Committee (HREC) approval to start a phase I/II clinical trialThe trial will assess one of Recce’s leading drug candidates, R327, as a spray-on antibiotic therapy to treat mild skin...

HITIQ signs with UK rugby league  Recce receives ethics approval to commence Phase 1/2 trial Healius appoints new CEO   HITIQ Limited (ASX: HIQ) rose 8% this morning after announcing a two-year commercial agreement with UK’s Rugby Footbal...

ASX 200 down 0.55% on lower than normal volume  Small cap index falls 0.96% and 10 out 11 sectors finish lower Economy grows for the fourth consecutive quarter, up 0.6%    The ASX200 was down 0.55% today, and the ASX Emerging Companies...

Recce Pharmaceuticals (RCE) has multiple trials in the pipeline following the September quarterRCE reported no serious adverse effects in the seventh cohort who were dosed with 6000mg of its R327 drug and the positive outcomes will see a ph...

It’s Tuesday afternoon, and after a long, hard day buying and selling bits of paper that say you own small portions of much larger things, you owe it to yourself to sit back and relax in front of a warm, crackling fire. So crack open a bott...

Recce Pharmaceuticals (RCE) reports that independent studies of its RECCE 327 (R327) product found the drug to significantly reduce SARS-CoV-2 in Syrian golden hamstersThe company says the study results provide it with proof of concept that...

Highlights: The ASX 200 benchmark index closed up today, gaining 0.41% to end at 6,496.20 points. Over the last five days, the index has lost 4.56% and has shed 12.03% over the last 52 weeks. Materials was the best performing sector,...